{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,5]],"date-time":"2026-10-05T21:32:31Z","timestamp":1791235951704,"version":"4.1.0"},"reference-count":168,"publisher":"Elsevier BV","issue":"1","license":[{"start":{"date-parts":[[2014,11,1]],"date-time":"2014-11-01T00:00:00Z","timestamp":1414800000000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2014,7,14]],"date-time":"2014-07-14T00:00:00Z","timestamp":1405296000000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0\/"}],"content-domain":{"domain":["journal-of-hepatology.eu","clinicalkey.jp","clinicalkey.com","clinicalkey.es","clinicalkey.com.au","clinicalkey.fr","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Journal of Hepatology"],"published-print":{"date-parts":[[2014,11]]},"DOI":"10.1016\/j.jhep.2014.07.010","type":"journal-article","created":{"date-parts":[[2014,11,3]],"date-time":"2014-11-03T01:16:05Z","timestamp":1414977365000},"page":"S79-S90","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":196,"special_numbering":"S","title":["Pathogenesis and prevention of hepatitis C virus-induced hepatocellular carcinoma"],"prefix":"10.1016","volume":"61","author":[{"given":"Yujin","family":"Hoshida","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Bryan C.","family":"Fuchs","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Nabeel","family":"Bardeesy","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Thomas F.","family":"Baumert","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Raymond T.","family":"Chung","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"key":"10.1016\/j.jhep.2014.07.010_b0005","doi-asserted-by":"crossref","first-page":"1118","DOI":"10.1056\/NEJMra1001683","article-title":"Hepatocellular carcinoma","volume":"365","author":"El-Serag","year":"2011","journal-title":"N Engl J Med"},{"key":"10.1016\/j.jhep.2014.07.010_b0010","doi-asserted-by":"crossref","first-page":"924","DOI":"10.1016\/j.cgh.2010.06.032","article-title":"Prevalence and challenges of liver diseases in patients with chronic hepatitis C virus infection","volume":"8","author":"Jacobson","year":"2010","journal-title":"Clin Gastroenterol Hepatol"},{"key":"10.1016\/j.jhep.2014.07.010_b0015","doi-asserted-by":"crossref","first-page":"243","DOI":"10.1155\/2014\/317623","article-title":"Burden of disease and cost of chronic hepatitis C infection in Canada","volume":"28","author":"Myers","year":"2014","journal-title":"Can J Gastroenterol Hepatol"},{"key":"10.1016\/j.jhep.2014.07.010_b0020","first-page":"1129","article-title":"Prevention of hepatocellular carcinoma: potential targets, experimental models, and clinical challenges","volume":"12","author":"Hoshida","year":"2012","journal-title":"Curr Cancer Drug Targets"},{"key":"10.1016\/j.jhep.2014.07.010_b0025","doi-asserted-by":"crossref","first-page":"3040","DOI":"10.1001\/jama.284.23.3040","article-title":"Hepatitis B vaccination and hepatocellular carcinoma rates in boys and girls","volume":"284","author":"Chang","year":"2000","journal-title":"JAMA"},{"key":"10.1016\/j.jhep.2014.07.010_b0030","doi-asserted-by":"crossref","first-page":"174","DOI":"10.7326\/0003-4819-131-3-199908030-00003","article-title":"Interferon therapy reduces the risk for hepatocellular carcinoma: national surveillance program of cirrhotic and noncirrhotic patients with chronic hepatitis C in Japan. IHIT Study Group. Inhibition of hepatocarcinogenesis by interferon therapy","volume":"131","author":"Yoshida","year":"1999","journal-title":"Ann Intern Med"},{"key":"10.1016\/j.jhep.2014.07.010_b0035","doi-asserted-by":"crossref","first-page":"448","DOI":"10.1038\/nrgastro.2010.100","article-title":"Hepatocellular carcinoma: a global view","volume":"7","author":"Yang","year":"2010","journal-title":"Nat Rev Gastroenterol Hepatol"},{"key":"10.1016\/j.jhep.2014.07.010_b0040","doi-asserted-by":"crossref","first-page":"1576","DOI":"10.1056\/NEJMp1400986","article-title":"Curing chronic hepatitis C \u2013 The arc of a medical triumph","volume":"370","author":"Chung","year":"2014","journal-title":"N Engl J Med"},{"key":"10.1016\/j.jhep.2014.07.010_b0045","doi-asserted-by":"crossref","first-page":"2584","DOI":"10.1001\/jama.2012.144878","article-title":"Association between sustained virological response and all-cause mortality among patients with chronic hepatitis C and advanced hepatic fibrosis","volume":"308","author":"van der Meer","year":"2012","journal-title":"JAMA"},{"key":"10.1016\/j.jhep.2014.07.010_b0050","doi-asserted-by":"crossref","first-page":"S132","DOI":"10.1016\/S1542-3565(05)00700-7","article-title":"Molecular basis of hepatitis C virus-associated hepatocarcinogenesis: lessons from animal model studies","volume":"3","author":"Koike","year":"2005","journal-title":"Clin Gastroenterol Hepatol"},{"key":"10.1016\/j.jhep.2014.07.010_b0055","doi-asserted-by":"crossref","first-page":"213","DOI":"10.3389\/fmicb.2013.00212","article-title":"Hepatitis C virus infection and related liver disease: the quest for the best animal model","volume":"4","author":"Mailly","year":"2013","journal-title":"Front Microbiol"},{"key":"10.1016\/j.jhep.2014.07.010_b0060","first-page":"49","article-title":"Animal models for hepatitis C","volume":"369","author":"Billerbeck","year":"2013","journal-title":"Curr Top Microbiol Immunol"},{"key":"10.1016\/j.jhep.2014.07.010_b0065","doi-asserted-by":"crossref","first-page":"482","DOI":"10.1038\/nrmicro3046","article-title":"The molecular and structural basis of advanced antiviral therapy for hepatitis C virus infection","volume":"11","author":"Bartenschlager","year":"2013","journal-title":"Nat Rev Microbiol"},{"key":"10.1016\/j.jhep.2014.07.010_b0070","doi-asserted-by":"crossref","first-page":"381","DOI":"10.1038\/nature13117","article-title":"Structure of the core ectodomain of the hepatitis C virus envelope glycoprotein 2","volume":"509","author":"Khan","year":"2014","journal-title":"Nature"},{"key":"10.1016\/j.jhep.2014.07.010_b0075","first-page":"87","article-title":"Hepatitis C virus entry","volume":"369","author":"Zeisel","year":"2013","journal-title":"Curr Top Microbiol Immunol"},{"key":"10.1016\/j.jhep.2014.07.010_b0080","doi-asserted-by":"crossref","first-page":"173","DOI":"10.1016\/j.canlet.2010.10.002","article-title":"Impact of viral load of hepatitis C on the incidence of hepatocellular carcinoma: a population-based cohort study (JPHC Study)","volume":"300","author":"Ishiguro","year":"2011","journal-title":"Cancer Lett"},{"key":"10.1016\/j.jhep.2014.07.010_b0085","doi-asserted-by":"crossref","first-page":"4587","DOI":"10.1200\/JCO.2010.29.1500","article-title":"Hepatitis C virus seromarkers and subsequent risk of hepatocellular carcinoma: long-term predictors from a community-based cohort study","volume":"28","author":"Lee","year":"2010","journal-title":"J Clin Oncol"},{"key":"10.1016\/j.jhep.2014.07.010_b0090","doi-asserted-by":"crossref","first-page":"106","DOI":"10.1016\/S0168-8278(00)80166-X","article-title":"Hepatocyte steatosis is a cytopathic effect of hepatitis C virus genotype 3","volume":"33","author":"Rubbia-Brandt","year":"2000","journal-title":"J Hepatol"},{"key":"10.1016\/j.jhep.2014.07.010_b0095","doi-asserted-by":"crossref","first-page":"1142","DOI":"10.1016\/j.jhep.2009.01.019","article-title":"Hepatitis C virus genotype 1b as a risk factor for hepatocellular carcinoma development: a meta-analysis","volume":"50","author":"Raimondi","year":"2009","journal-title":"J Hepatol"},{"key":"10.1016\/j.jhep.2014.07.010_b0100","doi-asserted-by":"crossref","first-page":"1096","DOI":"10.1002\/hep.20668","article-title":"Hepatitis C virus core protein stimulates hepatocyte growth: correlation with upregulation of wnt-1 expression","volume":"41","author":"Fukutomi","year":"2005","journal-title":"Hepatology"},{"key":"10.1016\/j.jhep.2014.07.010_b0105","doi-asserted-by":"crossref","first-page":"96","DOI":"10.1046\/j.1365-2893.2001.00283.x","article-title":"Cell transformation induced by hepatitis C virus NS3 serine protease","volume":"8","author":"Zemel","year":"2001","journal-title":"J Viral Hepat"},{"key":"10.1016\/j.jhep.2014.07.010_b0110","doi-asserted-by":"crossref","first-page":"12675","DOI":"10.1074\/jbc.M008329200","article-title":"Modulation of cell growth by the hepatitis C virus nonstructural protein NS5A","volume":"276","author":"Arima","year":"2001","journal-title":"J Biol Chem"},{"key":"10.1016\/j.jhep.2014.07.010_b0115","doi-asserted-by":"crossref","first-page":"1065","DOI":"10.1038\/2053","article-title":"The core protein of hepatitis C virus induces hepatocellular carcinoma in transgenic mice","volume":"4","author":"Moriya","year":"1998","journal-title":"Nat Med"},{"key":"10.1016\/j.jhep.2014.07.010_b0120","doi-asserted-by":"crossref","first-page":"2472","DOI":"10.1038\/sj.onc.1207368","article-title":"Modulation of p53 transcription regulatory activity and post-translational modification by hepatitis C virus core protein","volume":"23","author":"Kao","year":"2004","journal-title":"Oncogene"},{"key":"10.1016\/j.jhep.2014.07.010_b0125","doi-asserted-by":"crossref","first-page":"2573","DOI":"10.1038\/sj.onc.1206333","article-title":"Physical and functional interaction between HCV core protein and the different p73 isoforms","volume":"22","author":"Alisi","year":"2003","journal-title":"Oncogene"},{"key":"10.1016\/j.jhep.2014.07.010_b0130","doi-asserted-by":"crossref","first-page":"958","DOI":"10.1053\/jhep.2000.19343","article-title":"Hepatitis C virus core protein activates the MAPK\/ERK cascade synergistically with tumour promoter TPA, but not with epidermal growth factor or transforming growth factor alpha","volume":"32","author":"Hayashi","year":"2000","journal-title":"Hepatology"},{"key":"10.1016\/j.jhep.2014.07.010_b0135","doi-asserted-by":"crossref","first-page":"12590","DOI":"10.1128\/JVI.02643-08","article-title":"Hepatitis C virus causes uncoupling of mitotic checkpoint and chromosomal polyploidy through the Rb pathway","volume":"83","author":"Machida","year":"2009","journal-title":"J Virol"},{"key":"10.1016\/j.jhep.2014.07.010_b0140","doi-asserted-by":"crossref","first-page":"1703","DOI":"10.1099\/vir.0.81735-0","article-title":"NS3 protein of hepatitis C virus associates with the tumour suppressor p53 and inhibits its function in an NS3 sequence-dependent manner","volume":"87","author":"Deng","year":"2006","journal-title":"J Gen Virol"},{"key":"10.1016\/j.jhep.2014.07.010_b0145","doi-asserted-by":"crossref","first-page":"1401","DOI":"10.1128\/JVI.75.3.1401-1407.2001","article-title":"Hepatitis C virus NS5A physically associates with p53 and regulates p21\/waf1 gene expression in a p53-dependent manner","volume":"75","author":"Majumder","year":"2001","journal-title":"J Virol"},{"key":"10.1016\/j.jhep.2014.07.010_b0150","doi-asserted-by":"crossref","first-page":"18159","DOI":"10.1073\/pnas.0505605102","article-title":"Down-regulation of the retinoblastoma tumour suppressor by the hepatitis C virus NS5B RNA-dependent RNA polymerase","volume":"102","author":"Munakata","year":"2005","journal-title":"Proc Natl Acad Sci U S A"},{"key":"10.1016\/j.jhep.2014.07.010_b0155","doi-asserted-by":"crossref","first-page":"23","DOI":"10.1016\/j.yexcr.2004.12.024","article-title":"Hepatitis C virus E2 protein promotes human hepatoma cell proliferation through the MAPK\/ERK signalling pathway via cellular receptors","volume":"305","author":"Zhao","year":"2005","journal-title":"Exp Cell Res"},{"key":"10.1016\/j.jhep.2014.07.010_b0160","doi-asserted-by":"crossref","first-page":"1736","DOI":"10.1128\/JVI.74.4.1736-1741.2000","article-title":"Hepatitis C virus core protein interacts with 14-3-3 protein and activates the kinase Raf-1","volume":"74","author":"Aoki","year":"2000","journal-title":"J Virol"},{"key":"10.1016\/j.jhep.2014.07.010_b0165","doi-asserted-by":"crossref","first-page":"5533","DOI":"10.1073\/pnas.96.10.5533","article-title":"NS5A, a nonstructural protein of hepatitis C virus, binds growth factor receptor-bound protein 2 adaptor protein in a Src homology 3 domain\/ligand-dependent manner and perturbs mitogenic signalling","volume":"96","author":"Tan","year":"1999","journal-title":"Proc Natl Acad Sci U S A"},{"key":"10.1016\/j.jhep.2014.07.010_b0170","doi-asserted-by":"crossref","first-page":"S108","DOI":"10.1111\/j.1440-1746.2006.04669.x","article-title":"Hepatitis C virus contributes to hepatocarcinogenesis by modulating metabolic and intracellular signalling pathways","volume":"22","author":"Koike","year":"2007","journal-title":"J Gastroenterol Hepatol"},{"key":"10.1016\/j.jhep.2014.07.010_b0175","doi-asserted-by":"crossref","first-page":"550","DOI":"10.1016\/j.jhep.2010.01.015","article-title":"IGF activation in a molecular subclass of hepatocellular carcinoma and pre-clinical efficacy of IGF-1R blockage","volume":"52","author":"Tovar","year":"2010","journal-title":"J Hepatol"},{"key":"10.1016\/j.jhep.2014.07.010_b0180","doi-asserted-by":"crossref","first-page":"5006","DOI":"10.1128\/JVI.79.8.5006-5016.2005","article-title":"Hepatitis C virus NS5A-mediated activation of phosphoinositide 3-kinase results in stabilization of cellular beta-catenin and stimulation of beta-catenin-responsive transcription","volume":"79","author":"Street","year":"2005","journal-title":"J Virol"},{"key":"10.1016\/j.jhep.2014.07.010_b0185","doi-asserted-by":"crossref","first-page":"29","DOI":"10.1046\/j.1365-2893.1997.00124.x","article-title":"Transforming growth factor-beta 1 in chronic hepatitis C","volume":"4","author":"Nelson","year":"1997","journal-title":"J Viral Hepat"},{"issue":"40","key":"10.1016\/j.jhep.2014.07.010_b0845","doi-asserted-by":"crossref","first-page":"6119","DOI":"10.1038\/sj.onc.1208749","article-title":"Hepatitis C virus core variants isolated from liver tumor but not from adjacent non-tumor tissue interact with Smad3 and inhibit the TGF-beta pathway","volume":"24","author":"Pavio","year":"2005","journal-title":"Oncogene"},{"key":"10.1016\/j.jhep.2014.07.010_b0195","doi-asserted-by":"crossref","first-page":"2832","DOI":"10.1172\/JCI65859","article-title":"Reciprocal regulation by TLR4 and TGF-beta in tumour-initiating stem-like cells","volume":"123","author":"Chen","year":"2013","journal-title":"J Clin Invest"},{"key":"10.1016\/j.jhep.2014.07.010_b0200","doi-asserted-by":"crossref","first-page":"7468","DOI":"10.1074\/jbc.M512438200","article-title":"Modulation of the transforming growth factor-beta signal transduction pathway by hepatitis C virus nonstructural 5A protein","volume":"281","author":"Choi","year":"2006","journal-title":"J Biol Chem"},{"key":"10.1016\/j.jhep.2014.07.010_b0205","doi-asserted-by":"crossref","first-page":"29396","DOI":"10.1074\/jbc.M802821200","article-title":"Hepatitis C virus NS5A protein down-regulates the expression of spindle gene Aspm through PKR-p38 signalling pathway","volume":"283","author":"Wu","year":"2008","journal-title":"J Biol Chem"},{"key":"10.1016\/j.jhep.2014.07.010_b0210","doi-asserted-by":"crossref","first-page":"173","DOI":"10.1016\/S0168-1702(00)00141-6","article-title":"Hepatitis C virus NS5A protein protects against TNF-alpha mediated apoptotic cell death","volume":"67","author":"Ghosh","year":"2000","journal-title":"Virus Res"},{"key":"10.1016\/j.jhep.2014.07.010_b0215","doi-asserted-by":"crossref","first-page":"12292","DOI":"10.1128\/JVI.05920-11","article-title":"Hepatitis C virus-induced cancer stem cell-like signatures in cell culture and murine tumour xenografts","volume":"85","author":"Ali","year":"2011","journal-title":"J Virol"},{"key":"10.1016\/j.jhep.2014.07.010_b0220","doi-asserted-by":"crossref","first-page":"369","DOI":"10.1111\/j.1349-7006.2008.01045.x","article-title":"Strategy and mechanism for the prevention of hepatocellular carcinoma: phosphorylated retinoid X receptor alpha is a critical target for hepatocellular carcinoma chemoprevention","volume":"100","author":"Shimizu","year":"2009","journal-title":"Cancer Sci"},{"key":"10.1016\/j.jhep.2014.07.010_b0225","doi-asserted-by":"crossref","first-page":"1925","DOI":"10.1053\/j.gastro.2007.02.038","article-title":"Inhibition of T-cell inflammatory cytokines, hepatocyte NF-\u03baB signalling, and HCV infection by standardized silymarin","volume":"132","author":"Polyak","year":"2007","journal-title":"Gastroenterology"},{"key":"10.1016\/j.jhep.2014.07.010_b0230","doi-asserted-by":"crossref","first-page":"102","DOI":"10.1177\/1740774511427064","article-title":"Rationale, challenges, and participants in a phase II trial of a botanical product for chronic hepatitis C","volume":"9","author":"Reddy","year":"2012","journal-title":"Clin Trials"},{"key":"10.1016\/j.jhep.2014.07.010_b0235","doi-asserted-by":"crossref","first-page":"127","DOI":"10.1111\/j.1365-2036.2010.04503.x","article-title":"Silymarin use and liver disease progression in the hepatitis C antiviral long-term treatment against cirrhosis trial","volume":"33","author":"Freedman","year":"2011","journal-title":"Aliment Pharmacol Ther"},{"key":"10.1016\/j.jhep.2014.07.010_b0240","doi-asserted-by":"crossref","first-page":"295","DOI":"10.1016\/j.virol.2007.08.037","article-title":"Hepatitis C virus NS3\/4A protein interacts with ATM, impairs DNA repair and enhances sensitivity to ionizing radiation","volume":"370","author":"Lai","year":"2008","journal-title":"Virology"},{"key":"10.1016\/j.jhep.2014.07.010_b0245","doi-asserted-by":"crossref","first-page":"7453","DOI":"10.1128\/JVI.76.15.7453-7459.2002","article-title":"Hepatitis C virus subgenomic replicons induce endoplasmic reticulum stress activating an intracellular signalling pathway","volume":"76","author":"Tardif","year":"2002","journal-title":"J Virol"},{"key":"10.1016\/j.jhep.2014.07.010_b0250","doi-asserted-by":"crossref","first-page":"67","DOI":"10.1016\/j.it.2012.10.004","article-title":"Type I interferon response and innate immune sensing of cancer","volume":"34","author":"Fuertes","year":"2013","journal-title":"Trends Immunol"},{"key":"10.1016\/j.jhep.2014.07.010_b0255","doi-asserted-by":"crossref","first-page":"461","DOI":"10.1038\/nature02924","article-title":"NF-\u03baB functions as a tumour promoter in inflammation-associated cancer","volume":"431","author":"Pikarsky","year":"2004","journal-title":"Nature"},{"key":"10.1016\/j.jhep.2014.07.010_b0260","doi-asserted-by":"crossref","first-page":"108","DOI":"10.1038\/nrgastro.2010.213","article-title":"NF-\u03baB in the liver-linking injury, fibrosis and hepatocellular carcinoma","volume":"8","author":"Luedde","year":"2011","journal-title":"Nat Rev Gastroenterol Hepatol"},{"key":"10.1016\/j.jhep.2014.07.010_b0265","doi-asserted-by":"crossref","first-page":"7648","DOI":"10.1128\/JVI.79.12.7648-7657.2005","article-title":"Hepatitis C virus core protein suppresses NF-\u03baB activation and cyclooxygenase-2 expression by direct interaction with IkappaB kinase beta","volume":"79","author":"Joo","year":"2005","journal-title":"J Virol"},{"key":"10.1016\/j.jhep.2014.07.010_b0270","doi-asserted-by":"crossref","first-page":"3943","DOI":"10.1172\/JCI37156","article-title":"Proliferation of human HCC cells and chemically induced mouse liver cancers requires JNK1-dependent p21 downregulation","volume":"118","author":"Hui","year":"2008","journal-title":"J Clin Invest"},{"key":"10.1016\/j.jhep.2014.07.010_b0275","doi-asserted-by":"crossref","first-page":"30711","DOI":"10.1074\/jbc.M209623200","article-title":"1Hepatitis C virus NS5A protein modulates c-Jun N-terminal kinase through interaction with tumour necrosis factor receptor-associated factor 2","volume":"278","author":"Park","year":"2003","journal-title":"J Biol Chem"},{"key":"10.1016\/j.jhep.2014.07.010_b0280","doi-asserted-by":"crossref","first-page":"1944","DOI":"10.1002\/hep.22860","article-title":"Inhibition of c-Jun NH2-terminal kinase switches Smad3 signalling from oncogenesis to tumour-suppression in rat hepatocellular carcinoma","volume":"49","author":"Nagata","year":"2009","journal-title":"Hepatology"},{"key":"10.1016\/j.jhep.2014.07.010_b0285","doi-asserted-by":"crossref","first-page":"319","DOI":"10.1016\/j.biopha.2009.09.023","article-title":"Preventive effect of JTE-522, a selective cyclooxygenase-2 inhibitor, on DEN-induced hepatocarcinogenesis in rats","volume":"64","author":"Nagahara","year":"2010","journal-title":"Biomed Pharmacother"},{"key":"10.1016\/j.jhep.2014.07.010_b0290","doi-asserted-by":"crossref","first-page":"295","DOI":"10.1016\/j.ccr.2009.08.021","article-title":"A lymphotoxin-driven pathway to hepatocellular carcinoma","volume":"16","author":"Haybaeck","year":"2009","journal-title":"Cancer Cell"},{"key":"10.1016\/j.jhep.2014.07.010_b0295","doi-asserted-by":"crossref","first-page":"17717","DOI":"10.1073\/pnas.0508531102","article-title":"Hepatitis C virus protease NS3\/4A cleaves mitochondrial antiviral signalling protein off the mitochondria to evade innate immunity","volume":"102","author":"Li","year":"2005","journal-title":"Proc Natl Acad Sci U S A"},{"key":"10.1016\/j.jhep.2014.07.010_b0300","doi-asserted-by":"crossref","first-page":"43","DOI":"10.1084\/jem.20011145","article-title":"Binding of the hepatitis C virus envelope protein E2 to CD81 inhibits natural killer cell functions","volume":"195","author":"Tseng","year":"2002","journal-title":"J Exp Med"},{"key":"10.1016\/j.jhep.2014.07.010_b0305","doi-asserted-by":"crossref","first-page":"121","DOI":"10.1126\/science.1140485","article-title":"Gender disparity in liver cancer due to sex differences in MyD88-dependent IL-6 production","volume":"317","author":"Naugler","year":"2007","journal-title":"Science"},{"key":"10.1016\/j.jhep.2014.07.010_b0310","doi-asserted-by":"crossref","first-page":"10847","DOI":"10.1074\/jbc.M110.217653","article-title":"Extracellular hepatitis C virus core protein activates STAT3 in human monocytes\/macrophages\/dendritic cells via an IL-6 autocrine pathway","volume":"286","author":"Tacke","year":"2011","journal-title":"J Biol Chem"},{"key":"10.1016\/j.jhep.2014.07.010_b0315","doi-asserted-by":"crossref","first-page":"96","DOI":"10.1111\/j.1440-1746.2010.06542.x","article-title":"Hepatic steatosis and hepatitis C: still unhappy bedfellows?","volume":"26","author":"Hwang","year":"2011","journal-title":"J Gastroenterol Hepatol"},{"key":"10.1016\/j.jhep.2014.07.010_b0320","doi-asserted-by":"crossref","first-page":"1200","DOI":"10.1073\/pnas.94.4.1200","article-title":"Hepatitis C virus core protein shows a cytoplasmic localization and associates to cellular lipid storage droplets","volume":"94","author":"Barba","year":"1997","journal-title":"Proc Natl Acad Sci U S A"},{"key":"10.1016\/j.jhep.2014.07.010_b0325","doi-asserted-by":"crossref","first-page":"329","DOI":"10.1007\/s00535-005-1586-z","article-title":"Metabolic aspects of hepatitis C viral infection: steatohepatitis resembling but distinct from NASH","volume":"40","author":"Koike","year":"2005","journal-title":"J Gastroenterol"},{"key":"10.1016\/j.jhep.2014.07.010_b0330","doi-asserted-by":"crossref","first-page":"185","DOI":"10.1096\/fj.01-0396com","article-title":"Hepatitis C virus core protein inhibits microsomal triglyceride transfer protein activity and very low density lipoprotein secretion: a model of viral-related steatosis","volume":"16","author":"Perlemuter","year":"2002","journal-title":"FASEB J"},{"key":"10.1016\/j.jhep.2014.07.010_b0335","first-page":"683","article-title":"PPARalpha activation is essential for HCV core protein-induced hepatic steatosis and hepatocellular carcinoma in mice","volume":"118","author":"Tanaka","year":"2008","journal-title":"J Clin Invest"},{"key":"10.1016\/j.jhep.2014.07.010_b0340","doi-asserted-by":"crossref","first-page":"82","DOI":"10.1007\/s00535-008-2276-4","article-title":"Steatosis, liver injury, and hepatocarcinogenesis in hepatitis C viral infection","volume":"44","author":"Koike","year":"2009","journal-title":"J Gastroenterol"},{"key":"10.1016\/j.jhep.2014.07.010_b0345","doi-asserted-by":"crossref","first-page":"501","DOI":"10.1016\/S1097-2765(04)00256-4","article-title":"Telomere shortening triggers senescence of human cells through a pathway involving ATM, p53, and p21(CIP1), but not p16(INK4a)","volume":"14","author":"Herbig","year":"2004","journal-title":"Mol Cell"},{"key":"10.1016\/j.jhep.2014.07.010_b0350","doi-asserted-by":"crossref","first-page":"2218","DOI":"10.1038\/ncomms3218","article-title":"High frequency of telomerase reverse-transcriptase promoter somatic mutations in hepatocellular carcinoma and preneoplastic lesions","volume":"4","author":"Nault","year":"2013","journal-title":"Nat Commun"},{"key":"10.1016\/j.jhep.2014.07.010_b0355","doi-asserted-by":"crossref","first-page":"154","DOI":"10.1016\/j.canlet.2012.01.044","article-title":"Hepatitis C virus core protein overcomes stress-induced premature senescence by down-regulating p16 expression via DNA methylation","volume":"321","author":"Lim","year":"2012","journal-title":"Cancer Lett"},{"key":"10.1016\/j.jhep.2014.07.010_b0360","doi-asserted-by":"crossref","first-page":"657","DOI":"10.1016\/j.cell.2008.06.049","article-title":"Senescence of activated stellate cells limits liver fibrosis","volume":"134","author":"Krizhanovsky","year":"2008","journal-title":"Cell"},{"key":"10.1016\/j.jhep.2014.07.010_b0365","doi-asserted-by":"crossref","first-page":"1805","DOI":"10.1016\/0016-5085(94)90824-9","article-title":"Clonal analysis of regenerative nodules in hepatitis C virus-induced liver cirrhosis","volume":"107","author":"Aihara","year":"1994","journal-title":"Gastroenterology"},{"key":"10.1016\/j.jhep.2014.07.010_b0370","doi-asserted-by":"crossref","first-page":"S35","DOI":"10.1053\/j.gastro.2004.09.014","article-title":"Hepatocellular carcinoma in cirrhosis: incidence and risk factors","volume":"127","author":"Fattovich","year":"2004","journal-title":"Gastroenterology"},{"key":"10.1016\/j.jhep.2014.07.010_b0375","doi-asserted-by":"crossref","first-page":"23","DOI":"10.1016\/j.antiviral.2014.03.012","article-title":"Reversal, maintenance or progression: what happens to the liver after a virologic cure of hepatitis C?","volume":"107C","author":"Lee","year":"2014","journal-title":"Antiviral Res"},{"key":"10.1016\/j.jhep.2014.07.010_b0380","doi-asserted-by":"crossref","first-page":"512","DOI":"10.1053\/j.gastro.2013.01.002","article-title":"Role of the microenvironment in the pathogenesis and treatment of hepatocellular carcinoma","volume":"144","author":"Hernandez-Gea","year":"2013","journal-title":"Gastroenterology"},{"key":"10.1016\/j.jhep.2014.07.010_b0385","doi-asserted-by":"crossref","first-page":"425","DOI":"10.1038\/nrgastro.2010.97","article-title":"Evolving challenges in hepatic fibrosis","volume":"7","author":"Friedman","year":"2010","journal-title":"Nat Rev Gastroenterol Hepatol"},{"key":"10.1016\/j.jhep.2014.07.010_b0390","doi-asserted-by":"crossref","first-page":"529","DOI":"10.1053\/j.gastro.2003.11.018","article-title":"Hepatitis C virus core and nonstructural proteins induce fibrogenic effects in hepatic stellate cells","volume":"126","author":"Bataller","year":"2004","journal-title":"Gastroenterology"},{"key":"10.1016\/j.jhep.2014.07.010_b0395","doi-asserted-by":"crossref","first-page":"2509","DOI":"10.1053\/j.gastro.2010.03.008","article-title":"Hepatitis C virus regulates transforming growth factor beta1 production through the generation of reactive oxygen species in a nuclear factor kappaB-dependent manner","volume":"138","author":"Lin","year":"2010","journal-title":"Gastroenterology"},{"key":"10.1016\/j.jhep.2014.07.010_b0400","doi-asserted-by":"crossref","first-page":"1294","DOI":"10.1002\/hep.23123","article-title":"Targeting liver fibrosis: strategies for development and validation of antifibrotic therapies","volume":"50","author":"Popov","year":"2009","journal-title":"Hepatology"},{"key":"10.1016\/j.jhep.2014.07.010_b0405","doi-asserted-by":"crossref","first-page":"1617","DOI":"10.1038\/nm.3282","article-title":"Targeting of [alpha] v integrin identifies a core molecular pathway that regulates fibrosis in several organs","volume":"19","author":"Henderson","year":"2013","journal-title":"Nat Med"},{"key":"10.1016\/j.jhep.2014.07.010_b0410","doi-asserted-by":"crossref","first-page":"3389","DOI":"10.1073\/pnas.0409722102","article-title":"Platelet-derived growth factor C induces liver fibrosis, steatosis, and hepatocellular carcinoma","volume":"102","author":"Campbell","year":"2005","journal-title":"Proc Natl Acad Sci U S A"},{"issue":"17","key":"10.1016\/j.jhep.2014.07.010_b0415","doi-asserted-by":"crossref","first-page":"4459","DOI":"10.1158\/0008-5472.CAN-12-0028","article-title":"Acyclic retinoid targets platelet-derived growth factor signalling in the prevention of hepatic fibrosis and hepatocellular carcinoma development","volume":"72","author":"Okada","year":"2012","journal-title":"Cancer Res"},{"key":"10.1016\/j.jhep.2014.07.010_b0420","doi-asserted-by":"crossref","first-page":"48","DOI":"10.1002\/hep.21672","article-title":"Chronic inflammation associated with hepatitis C virus infection perturbs hepatic transforming growth factor beta signalling, promoting cirrhosis and hepatocellular carcinoma","volume":"46","author":"Matsuzaki","year":"2007","journal-title":"Hepatology"},{"key":"10.1016\/j.jhep.2014.07.010_b0425","doi-asserted-by":"crossref","first-page":"347","DOI":"10.1053\/j.gastro.2009.09.015","article-title":"Modulation of hepatic fibrosis by c-Jun-N-terminal kinase inhibition","volume":"138","author":"Kluwe","year":"2010","journal-title":"Gastroenterology"},{"issue":"6","key":"10.1016\/j.jhep.2014.07.010_b0430","doi-asserted-by":"crossref","first-page":"1819","DOI":"10.1002\/hep.24285","article-title":"IL-32: A new proinflammatory cytokine involved in HCV-related liver inflammation and fibrosis","volume":"53","author":"Moschen","year":"2011","journal-title":"Hepatology"},{"key":"10.1016\/j.jhep.2014.07.010_b0435","doi-asserted-by":"crossref","first-page":"402","DOI":"10.1055\/s-0030-1267540","article-title":"Apoptosis as a mechanism for liver disease progression","volume":"30","author":"Guicciardi","year":"2010","journal-title":"Semin Liver Dis"},{"key":"10.1016\/j.jhep.2014.07.010_b0440","doi-asserted-by":"crossref","first-page":"324","DOI":"10.1002\/hep.21664","article-title":"Oral IDN-6556, an antiapoptotic caspase inhibitor, may lower aminotransferase activity in patients with chronic hepatitis C","volume":"46","author":"Pockros","year":"2007","journal-title":"Hepatology"},{"key":"10.1016\/j.jhep.2014.07.010_b0445","doi-asserted-by":"crossref","first-page":"760","DOI":"10.1111\/j.1365-2893.2010.01362.x","article-title":"Hepatocyte apoptotic bodies encasing nonstructural HCV proteins amplify hepatic stellate cell activation: implications for chronic hepatitis C","volume":"18","author":"Gieseler","year":"2011","journal-title":"J Viral Hepat"},{"key":"10.1016\/j.jhep.2014.07.010_b0450","doi-asserted-by":"crossref","first-page":"504","DOI":"10.1016\/j.ccr.2012.02.007","article-title":"Promotion of hepatocellular carcinoma by the intestinal microbiota and TLR4","volume":"21","author":"Dapito","year":"2012","journal-title":"Cancer Cell"},{"key":"10.1016\/j.jhep.2014.07.010_b0455","doi-asserted-by":"crossref","first-page":"750","DOI":"10.1016\/j.jhep.2009.04.027","article-title":"Multiple variants in toll-like receptor 4 gene modulate risk of liver fibrosis in caucasians with chronic hepatitis C infection","volume":"51","author":"Li","year":"2009","journal-title":"J Hepatol"},{"key":"10.1016\/j.jhep.2014.07.010_b0460","doi-asserted-by":"crossref","first-page":"11329","DOI":"10.1074\/jbc.M410161200","article-title":"Binding of hepatitis C virus envelope protein E2 to CD81 up-regulates matrix metalloproteinase-2 in human hepatic stellate cells","volume":"280","author":"Mazzocca","year":"2005","journal-title":"J Biol Chem"},{"key":"10.1016\/j.jhep.2014.07.010_b0465","doi-asserted-by":"crossref","first-page":"957","DOI":"10.1002\/hep.23046","article-title":"Adipokines in liver diseases","volume":"50","author":"Marra","year":"2009","journal-title":"Hepatology"},{"key":"10.1016\/j.jhep.2014.07.010_b0470","doi-asserted-by":"crossref","first-page":"431","DOI":"10.1038\/nbt1396","article-title":"Resolution of liver cirrhosis using vitamin A-coupled liposomes to deliver siRNA against a collagen-specific chaperone","volume":"26","author":"Sato","year":"2008","journal-title":"Nat Biotechnol"},{"key":"10.1016\/j.jhep.2014.07.010_b0475","doi-asserted-by":"crossref","first-page":"e2331","DOI":"10.1053\/j.gastro.2009.02.081","article-title":"Angiotensin II activates I kappaB kinase phosphorylation of RelA at Ser 536 to promote myofibroblast survival and liver fibrosis","volume":"136","author":"Oakley","year":"2009","journal-title":"Gastroenterology"},{"key":"10.1016\/j.jhep.2014.07.010_b0480","doi-asserted-by":"crossref","first-page":"443","DOI":"10.1007\/s00535-009-0158-z","article-title":"Attenuation of insulin-resistance-based hepatocarcinogenesis and angiogenesis by combined treatment with branched-chain amino acids and angiotensin-converting enzyme inhibitor in obese diabetic rats","volume":"45","author":"Yoshiji","year":"2010","journal-title":"J Gastroenterol"},{"key":"10.1016\/j.jhep.2014.07.010_b0485","doi-asserted-by":"crossref","first-page":"1887","DOI":"10.1172\/JCI66028","article-title":"Evolving therapies for liver fibrosis","volume":"123","author":"Schuppan","year":"2013","journal-title":"J Clin Invest"},{"key":"10.1016\/j.jhep.2014.07.010_b0490","doi-asserted-by":"crossref","first-page":"1577","DOI":"10.1002\/hep.26898","article-title":"Epidermal growth factor receptor inhibition attenuates liver fibrosis and development of hepatocellular carcinoma","volume":"59","author":"Fuchs","year":"2014","journal-title":"Hepatology"},{"key":"10.1016\/j.jhep.2014.07.010_b0495","doi-asserted-by":"crossref","first-page":"307","DOI":"10.1002\/hep.20538","article-title":"Gefitinib, an EGFR inhibitor, prevents hepatocellular carcinoma development in the rat liver with cirrhosis","volume":"41","author":"Schiffer","year":"2005","journal-title":"Hepatology"},{"key":"10.1016\/j.jhep.2014.07.010_b0500","doi-asserted-by":"crossref","first-page":"589","DOI":"10.1038\/nm.2341","article-title":"EGFR and EphA2 are host factors for hepatitis C virus entry and possible targets for antiviral therapy","volume":"17","author":"Lupberger","year":"2011","journal-title":"Nat Med"},{"key":"10.1016\/j.jhep.2014.07.010_b0505","doi-asserted-by":"crossref","first-page":"302","DOI":"10.1016\/j.chom.2013.02.006","article-title":"HRas signal transduction promotes hepatitis C virus cell entry by triggering assembly of the host tetraspanin receptor complex","volume":"13","author":"Zona","year":"2013","journal-title":"Cell Host Microbe"},{"key":"10.1016\/j.jhep.2014.07.010_b0510","doi-asserted-by":"crossref","first-page":"2237","DOI":"10.1099\/vir.0.032581-0","article-title":"Hepatitis C virus infection induces the expression of amphiregulin, a factor related to the activation of cellular survival pathways and required for efficient viral assembly","volume":"92","author":"Pei","year":"2011","journal-title":"J Gen Virol"},{"key":"10.1016\/j.jhep.2014.07.010_b0515","doi-asserted-by":"crossref","first-page":"455","DOI":"10.1111\/j.1872-034X.2011.00792.x","article-title":"HCV core protein promotes heparin binding EGF-like growth factor expression and activates Akt","volume":"41","author":"Nakamura","year":"2011","journal-title":"Hepatol Res"},{"key":"10.1016\/j.jhep.2014.07.010_b0520","doi-asserted-by":"crossref","first-page":"1251","DOI":"10.1002\/hep.22437","article-title":"The epidermal growth factor receptor ligand amphiregulin participates in the development of mouse liver fibrosis","volume":"48","author":"Perugorria","year":"2008","journal-title":"Hepatology"},{"key":"10.1016\/j.jhep.2014.07.010_b0525","doi-asserted-by":"crossref","first-page":"703","DOI":"10.1038\/labinvest.2012.3","article-title":"Heparin-binding epidermal growth factor-like growth factor suppresses experimental liver fibrosis in mice","volume":"92","author":"Huang","year":"2012","journal-title":"Lab Invest"},{"key":"10.1016\/j.jhep.2014.07.010_b0530","doi-asserted-by":"crossref","first-page":"e16978","DOI":"10.1371\/journal.pone.0016978","article-title":"Reversible decrease of portal venous flow in cirrhotic patients: a positive side effect of sorafenib","volume":"6","author":"Coriat","year":"2011","journal-title":"PLoS One"},{"issue":"6","key":"10.1016\/j.jhep.2014.07.010_b0535","doi-asserted-by":"crossref","first-page":"730","DOI":"10.1158\/2159-8290.CD-13-0782","article-title":"Human and mouse VEGFA-amplified hepatocellular carcinomas are highly sensitive to sorafenib treatment","volume":"4","author":"Horwitz","year":"2014","journal-title":"Cancer Discov"},{"key":"10.1016\/j.jhep.2014.07.010_b0540","doi-asserted-by":"crossref","first-page":"399","DOI":"10.1038\/nature08309","article-title":"Genetic variation in IL28B predicts hepatitis C treatment-induced viral clearance","volume":"461","author":"Ge","year":"2009","journal-title":"Nature"},{"key":"10.1016\/j.jhep.2014.07.010_b0545","doi-asserted-by":"crossref","first-page":"716","DOI":"10.1016\/j.jhep.2010.07.019","article-title":"IL-28B rs12979860 C\/T allele distribution in patients with liver cirrhosis: role in the course of chronic viral hepatitis and the development of HCC","volume":"54","author":"Fabris","year":"2011","journal-title":"J Hepatol"},{"key":"10.1016\/j.jhep.2014.07.010_b0550","doi-asserted-by":"crossref","first-page":"1438","DOI":"10.1053\/j.gastro.2013.02.026","article-title":"A genetic screen identifies interferon-alpha effector genes required to suppress hepatitis C virus replication","volume":"144","author":"Fusco","year":"2013","journal-title":"Gastroenterology"},{"key":"10.1016\/j.jhep.2014.07.010_b0555","doi-asserted-by":"crossref","first-page":"455","DOI":"10.1038\/ng.809","article-title":"Genome-wide association study identifies a susceptibility locus for HCV-induced hepatocellular carcinoma","volume":"43","author":"Kumar","year":"2011","journal-title":"Nat Genet"},{"key":"10.1016\/j.jhep.2014.07.010_b0560","doi-asserted-by":"crossref","first-page":"5423","DOI":"10.4049\/jimmunol.171.10.5423","article-title":"Autocrine\/paracrine IL-15 that is required for type I IFN-mediated dendritic cell expression of MHC class I-related chain A and B is impaired in hepatitis C virus infection","volume":"171","author":"Jinushi","year":"2003","journal-title":"J Immunol"},{"key":"10.1016\/j.jhep.2014.07.010_b0565","doi-asserted-by":"crossref","first-page":"e61279","DOI":"10.1371\/journal.pone.0061279","article-title":"Identification of a functional variant in the MICA promoter which regulates MICA expression and increases HCV-related hepatocellular carcinoma risk","volume":"8","author":"Lo","year":"2013","journal-title":"PLoS One"},{"key":"10.1016\/j.jhep.2014.07.010_b0570","doi-asserted-by":"crossref","first-page":"729","DOI":"10.1016\/j.jhep.2011.08.015","article-title":"Genomic risk of hepatitis C-related hepatocellular carcinoma","volume":"56","author":"Hoshida","year":"2012","journal-title":"J Hepatol"},{"key":"10.1016\/j.jhep.2014.07.010_b0575","doi-asserted-by":"crossref","first-page":"504","DOI":"10.1016\/j.jhep.2013.04.032","article-title":"Comparative genetic analyses point to HCP5 as susceptibility locus for HCV-associated hepatocellular carcinoma","volume":"59","author":"Lange","year":"2013","journal-title":"J Hepatol"},{"issue":"8","key":"10.1016\/j.jhep.2014.07.010_b0580","doi-asserted-by":"crossref","first-page":"797","DOI":"10.1038\/ng.876","article-title":"Variation in the DEPDC5 locus is associated with progression to hepatocellular carcinoma in chronic hepatitis C virus carriers","volume":"43","author":"Miki","year":"2011","journal-title":"Nat Genet"},{"issue":"3","key":"10.1016\/j.jhep.2014.07.010_b0585","doi-asserted-by":"crossref","first-page":"325","DOI":"10.1038\/ajg.2013.476","article-title":"The effect of PNPLA3 on fibrosis progression and development of hepatocellular carcinoma: a meta-analysis","volume":"109","author":"Singal","year":"2014","journal-title":"Am J Gastroenterol"},{"key":"10.1016\/j.jhep.2014.07.010_b0590","doi-asserted-by":"crossref","first-page":"1394","DOI":"10.1111\/j.1478-3231.2007.01596.x","article-title":"Prevalence of hepatic iron overload and association with hepatocellular cancer in end-stage liver disease: results from the National Hemochromatosis Transplant Registry","volume":"27","author":"Ko","year":"2007","journal-title":"Liver Int"},{"key":"10.1016\/j.jhep.2014.07.010_b0595","doi-asserted-by":"crossref","first-page":"498","DOI":"10.1111\/j.1365-2893.2008.00972.x","article-title":"Comparison of hepatic oxidative DNA damage in patients with chronic hepatitis B and C","volume":"15","author":"Fujita","year":"2008","journal-title":"J Viral Hepat"},{"key":"10.1016\/j.jhep.2014.07.010_b0600","doi-asserted-by":"crossref","first-page":"2087","DOI":"10.1053\/j.gastro.2006.02.060","article-title":"Hepatic iron overload induces hepatocellular carcinoma in transgenic mice expressing the hepatitis C virus polyprotein","volume":"130","author":"Furutani","year":"2006","journal-title":"Gastroenterology"},{"key":"10.1016\/j.jhep.2014.07.010_b0605","doi-asserted-by":"crossref","first-page":"1440","DOI":"10.1053\/j.gastro.2006.08.036","article-title":"Roles of iron and HFE mutations on severity and response to therapy during retreatment of advanced chronic hepatitis C","volume":"131","author":"Bonkovsky","year":"2006","journal-title":"Gastroenterology"},{"key":"10.1016\/j.jhep.2014.07.010_b0610","doi-asserted-by":"crossref","first-page":"1223","DOI":"10.1002\/hep.22158","article-title":"MicroRNA gene expression profile of hepatitis C virus-associated hepatocellular carcinoma","volume":"47","author":"Varnholt","year":"2008","journal-title":"Hepatology"},{"key":"10.1016\/j.jhep.2014.07.010_b0615","doi-asserted-by":"crossref","first-page":"1098","DOI":"10.1002\/hep.22749","article-title":"Differential microRNA expression between hepatitis B and hepatitis C leading disease progression to hepatocellular carcinoma","volume":"49","author":"Ura","year":"2009","journal-title":"Hepatology"},{"key":"10.1016\/j.jhep.2014.07.010_b0620","doi-asserted-by":"crossref","first-page":"e1616","DOI":"10.1053\/j.gastro.2011.02.009","article-title":"MicroRNA-based classification of hepatocellular carcinoma and oncogenic role of miR-517a","volume":"140","author":"Toffanin","year":"2011","journal-title":"Gastroenterology"},{"key":"10.1016\/j.jhep.2014.07.010_b0625","doi-asserted-by":"crossref","first-page":"1577","DOI":"10.1126\/science.1113329","article-title":"Modulation of hepatitis C virus RNA abundance by a liver-specific MicroRNA","volume":"309","author":"Jopling","year":"2005","journal-title":"Science"},{"key":"10.1016\/j.jhep.2014.07.010_b0630","doi-asserted-by":"crossref","first-page":"338","DOI":"10.1038\/ncomms1345","article-title":"MicroRNA122 is a key regulator of alpha-fetoprotein expression and influences the aggressiveness of hepatocellular carcinoma","volume":"2","author":"Kojima","year":"2011","journal-title":"Nat Commun"},{"key":"10.1016\/j.jhep.2014.07.010_b0635","doi-asserted-by":"crossref","first-page":"2871","DOI":"10.1172\/JCI63539","article-title":"Essential metabolic, anti-inflammatory, and anti-tumourigenic functions of miR-122 in liver","volume":"122","author":"Hsu","year":"2012","journal-title":"J Clin Invest"},{"key":"10.1016\/j.jhep.2014.07.010_b0640","doi-asserted-by":"crossref","first-page":"53","DOI":"10.1002\/hep.24016","article-title":"MicroRNA silencing of tumour suppressor DLC-1 promotes efficient hepatitis C virus replication in primary human hepatocytes","volume":"53","author":"Banaudha","year":"2011","journal-title":"Hepatology"},{"key":"10.1016\/j.jhep.2014.07.010_b0645","doi-asserted-by":"crossref","first-page":"1546","DOI":"10.1126\/science.1235122","article-title":"Cancer genome landscapes","volume":"339","author":"Vogelstein","year":"2013","journal-title":"Science"},{"key":"10.1016\/j.jhep.2014.07.010_b0650","doi-asserted-by":"crossref","first-page":"2429","DOI":"10.1056\/NEJMoa0707615","article-title":"Prolonged therapy of advanced chronic hepatitis C with low-dose peginterferon","volume":"359","author":"Di Bisceglie","year":"2008","journal-title":"N Engl J Med"},{"key":"10.1016\/j.jhep.2014.07.010_b0655","doi-asserted-by":"crossref","first-page":"1990","DOI":"10.1053\/j.gastro.2011.03.010","article-title":"Maintenance therapy with peginterferon alfa-2b does not prevent hepatocellular carcinoma in cirrhotic patients with chronic hepatitis C","volume":"140","author":"Bruix","year":"2011","journal-title":"Gastroenterology"},{"key":"10.1016\/j.jhep.2014.07.010_b0660","article-title":"Peretinoin after curative therapy of hepatitis C-related hepatocellular carcinoma: a randomized double-blind placebo-controlled study","author":"Okita","year":"2014","journal-title":"J Gastroenterol"},{"key":"10.1016\/j.jhep.2014.07.010_b0665","doi-asserted-by":"crossref","first-page":"39","DOI":"10.1001\/jama.2008.864","article-title":"Effect of selenium and vitamin E on risk of prostate cancer and other cancers: the Selenium and Vitamin E Cancer Prevention Trial (SELECT)","volume":"301","author":"Lippman","year":"2009","journal-title":"JAMA"},{"key":"10.1016\/j.jhep.2014.07.010_b0670","doi-asserted-by":"crossref","first-page":"5984","DOI":"10.1158\/1078-0432.CCR-07-4531","article-title":"The use of genomics in clinical trial design","volume":"14","author":"Simon","year":"2008","journal-title":"Clin Cancer Res"},{"key":"10.1016\/j.jhep.2014.07.010_b0675","doi-asserted-by":"crossref","first-page":"908","DOI":"10.1016\/j.jhep.2011.12.001","article-title":"EASL-EORTC clinical practice guidelines: management of hepatocellular carcinoma","volume":"56","author":"EASL-EORTC","year":"2012","journal-title":"J Hepatol"},{"key":"10.1016\/j.jhep.2014.07.010_b0680","doi-asserted-by":"crossref","first-page":"85","DOI":"10.7326\/0003-4819-154-2-201101180-00006","article-title":"Utilization of surveillance for hepatocellular carcinoma among hepatitis C virus-infected veterans in the United States","volume":"154","author":"Davila","year":"2011","journal-title":"Ann Intern Med"},{"key":"10.1016\/j.jhep.2014.07.010_b0685","doi-asserted-by":"crossref","first-page":"557","DOI":"10.1111\/j.1365-2036.2009.04062.x","article-title":"Systematic review: non-invasive methods of fibrosis analysis in chronic hepatitis C","volume":"30","author":"Smith","year":"2009","journal-title":"Aliment Pharmacol Ther"},{"key":"10.1016\/j.jhep.2014.07.010_b0690","doi-asserted-by":"crossref","first-page":"1723","DOI":"10.1038\/ajg.2013.332","article-title":"Machine learning algorithms outperform conventional regression models in predicting development of hepatocellular carcinoma","volume":"108","author":"Singal","year":"2013","journal-title":"Am J Gastroenterol"},{"key":"10.1016\/j.jhep.2014.07.010_b0695","doi-asserted-by":"crossref","first-page":"e1241","DOI":"10.1053\/j.gastro.2014.01.045","article-title":"A new laboratory-based algorithm to predict development of hepatocellular carcinoma in patients with hepatitis C and cirrhosis","volume":"146","author":"El-Serag","year":"2014","journal-title":"Gastroenterology"},{"key":"10.1016\/j.jhep.2014.07.010_b0700","doi-asserted-by":"crossref","first-page":"663","DOI":"10.1016\/j.jhep.2012.02.035","article-title":"Single nucleotide polymorphisms and risk of hepatocellular carcinoma in cirrhosis","volume":"57","author":"Nahon","year":"2012","journal-title":"J Hepatol"},{"key":"10.1016\/j.jhep.2014.07.010_b0705","doi-asserted-by":"crossref","first-page":"53","DOI":"10.1001\/jama.2007.65","article-title":"Epidermal growth factor gene functional polymorphism and the risk of hepatocellular carcinoma in patients with cirrhosis","volume":"299","author":"Tanabe","year":"2008","journal-title":"JAMA"},{"key":"10.1016\/j.jhep.2014.07.010_b0710","doi-asserted-by":"crossref","first-page":"141","DOI":"10.1053\/j.gastro.2011.03.045","article-title":"A functional polymorphism in the epidermal growth factor gene is associated with risk for hepatocellular carcinoma","volume":"141","author":"Abu Dayyeh","year":"2011","journal-title":"Gastroenterology"},{"key":"10.1016\/j.jhep.2014.07.010_b0715","doi-asserted-by":"crossref","first-page":"e32159","DOI":"10.1371\/journal.pone.0032159","article-title":"Epidermal growth factor gene polymorphism and risk of hepatocellular carcinoma: a meta-analysis","volume":"7","author":"Zhong","year":"2012","journal-title":"PLoS One"},{"key":"10.1016\/j.jhep.2014.07.010_b0720","doi-asserted-by":"crossref","first-page":"426","DOI":"10.1016\/j.jhep.2011.08.010","article-title":"A variant in myeloperoxidase promoter hastens the emergence of hepatocellular carcinoma in patients with HCV-related cirrhosis","volume":"56","author":"Nahon","year":"2012","journal-title":"J Hepatol"},{"key":"10.1016\/j.jhep.2014.07.010_b0725","doi-asserted-by":"crossref","first-page":"1038","DOI":"10.1002\/hep.23111","article-title":"A seven-gene signature (cirrhosis risk score) predicts liver fibrosis progression in patients with initially mild chronic hepatitis C","volume":"50","author":"Marcolongo","year":"2009","journal-title":"Hepatology"},{"key":"10.1016\/j.jhep.2014.07.010_b0730","doi-asserted-by":"crossref","first-page":"1024","DOI":"10.1053\/j.gastro.2013.01.021","article-title":"Prognostic gene-expression signature for patients with hepatitis C-related early-stage cirrhosis","volume":"144","author":"Hoshida","year":"2013","journal-title":"Gastroenterology"},{"key":"10.1016\/j.jhep.2014.07.010_b0735","doi-asserted-by":"crossref","first-page":"319","DOI":"10.1517\/17530059.2013.795146","article-title":"Circulating markers for prognosis of hepatocellular carcinoma","volume":"7","author":"Wong","year":"2013","journal-title":"Expert Opin Med Diagn"},{"key":"10.1016\/j.jhep.2014.07.010_b0740","doi-asserted-by":"crossref","first-page":"992","DOI":"10.1016\/j.jhep.2013.06.026","article-title":"Molecular MRI of collagen to diagnose and stage liver fibrosis","volume":"59","author":"Fuchs","year":"2013","journal-title":"J Hepatol"},{"key":"10.1016\/j.jhep.2014.07.010_b0745","doi-asserted-by":"crossref","first-page":"1543","DOI":"10.1002\/hep.21415","article-title":"Prevention of hepatocellular carcinoma recurrence with alpha-interferon after liver resection in HCV cirrhosis","volume":"44","author":"Mazzaferro","year":"2006","journal-title":"Hepatology"},{"key":"10.1016\/j.jhep.2014.07.010_b0750","doi-asserted-by":"crossref","first-page":"299","DOI":"10.7326\/0003-4819-138-4-200302180-00008","article-title":"Interferon therapy after tumour ablation improves prognosis in patients with hepatocellular carcinoma associated with hepatitis C virus","volume":"138","author":"Shiratori","year":"2003","journal-title":"Ann Intern Med"},{"key":"10.1016\/j.jhep.2014.07.010_b0755","doi-asserted-by":"crossref","first-page":"4646","DOI":"10.1002\/cncr.24673","article-title":"Clinical trials of note. Sorafenib as adjuvant treatment in the prevention of disease recurrence in patients with hepatocellular carcinoma (HCC) (STORM)","volume":"115","author":"Printz","year":"2009","journal-title":"Cancer"},{"key":"10.1016\/j.jhep.2014.07.010_b0760","doi-asserted-by":"crossref","first-page":"865","DOI":"10.1007\/s00535-003-1163-2","article-title":"Significance of multicentric cancer recurrence after potentially curative ablation of hepatocellular carcinoma: a longterm cohort study of 892 patients with viral cirrhosis","volume":"38","author":"Ikeda","year":"2003","journal-title":"J Gastroenterol"},{"issue":"5","key":"10.1016\/j.jhep.2014.07.010_b0765","doi-asserted-by":"crossref","first-page":"728","DOI":"10.1016\/j.cgh.2013.06.024","article-title":"Direct Acting Antiviral Agents and the Path to Interferon Independence","volume":"12","author":"Schmidt","year":"2014","journal-title":"Clin Gastroenterol Hepatol"},{"key":"10.1016\/j.jhep.2014.07.010_b0770","doi-asserted-by":"crossref","first-page":"1973","DOI":"10.1056\/NEJMoa1402869","article-title":"ABT-450\/r-ombitasvir and dasabuvir with ribavirin for hepatitis C with cirrhosis","volume":"370","author":"Poordad","year":"2014","journal-title":"N Engl J Med"},{"key":"10.1016\/j.jhep.2014.07.010_b0775","doi-asserted-by":"crossref","first-page":"517","DOI":"10.7326\/0003-4819-132-7-200004040-00002","article-title":"Histologic improvement of fibrosis in patients with hepatitis C who have sustained response to interferon therapy","volume":"132","author":"Shiratori","year":"2000","journal-title":"Ann Intern Med"},{"issue":"3","key":"10.1016\/j.jhep.2014.07.010_b0780","doi-asserted-by":"crossref","first-page":"840","DOI":"10.1053\/j.gastro.2010.11.050","article-title":"Maintenance peginterferon therapy and other factors associated with hepatocellular carcinoma in patients with advanced hepatitis C","volume":"140","author":"Lok","year":"2011","journal-title":"Gastroenterology"},{"key":"10.1016\/j.jhep.2014.07.010_b0785","doi-asserted-by":"crossref","first-page":"411","DOI":"10.1111\/apt.12185","article-title":"Meta-analysis: recurrence and survival following the use of sirolimus in liver transplantation for hepatocellular carcinoma","volume":"37","author":"Menon","year":"2013","journal-title":"Aliment Pharmacol Ther"},{"key":"10.1016\/j.jhep.2014.07.010_b0790","doi-asserted-by":"crossref","first-page":"1808","DOI":"10.1093\/jnci\/djs452","article-title":"Nonsteroidal anti-inflammatory drug use, chronic liver disease, and hepatocellular carcinoma","volume":"104","author":"Sahasrabuddhe","year":"2012","journal-title":"J Natl Cancer Inst"},{"key":"10.1016\/j.jhep.2014.07.010_b0795","doi-asserted-by":"crossref","first-page":"e29849","DOI":"10.1371\/journal.pone.0029849","article-title":"Lack of effect of lowering LDL cholesterol on cancer: meta-analysis of individual data from 175,000 people in 27 randomised trials of statin therapy","volume":"7","author":"Emberson","year":"2012","journal-title":"PLoS One"},{"key":"10.1016\/j.jhep.2014.07.010_b0800","doi-asserted-by":"crossref","first-page":"881","DOI":"10.1038\/ajg.2013.5","article-title":"Anti-diabetic medications and the risk of hepatocellular cancer: a systematic review and meta-analysis","volume":"108","author":"Singh","year":"2013","journal-title":"Am J Gastroenterol"},{"key":"10.1016\/j.jhep.2014.07.010_b0805","doi-asserted-by":"crossref","first-page":"e1411","DOI":"10.1016\/j.cgh.2013.04.039","article-title":"Coffee reduces risk for hepatocellular carcinoma: an updated meta-analysis","volume":"11","author":"Bravi","year":"2013","journal-title":"Clin Gastroenterol Hepatol"},{"key":"10.1016\/j.jhep.2014.07.010_b0810","doi-asserted-by":"crossref","first-page":"1947","DOI":"10.1002\/hep.24610","article-title":"The green tea polyphenol, epigallocatechin-3-gallate, inhibits hepatitis C virus entry","volume":"54","author":"Ciesek","year":"2011","journal-title":"Hepatology"},{"key":"10.1016\/j.jhep.2014.07.010_b0815","doi-asserted-by":"crossref","first-page":"2072","DOI":"10.1158\/1078-0432.CCR-13-0547","article-title":"Hepatocellular carcinoma: reasons for phase III failure and novel perspectives on trial design","volume":"20","author":"Llovet","year":"2014","journal-title":"Clin Cancer Res"},{"key":"10.1016\/j.jhep.2014.07.010_b0820","doi-asserted-by":"crossref","first-page":"487","DOI":"10.1038\/nrg3013","article-title":"Towards systematic functional characterization of cancer genomes","volume":"12","author":"Boehm","year":"2011","journal-title":"Nat Rev Genet"},{"key":"10.1016\/j.jhep.2014.07.010_b0825","doi-asserted-by":"crossref","first-page":"389","DOI":"10.1016\/j.cell.2013.03.026","article-title":"A direct in vivo RNAi screen identifies MKK4 as a key regulator of liver regeneration","volume":"153","author":"Wuestefeld","year":"2013","journal-title":"Cell"},{"key":"10.1016\/j.jhep.2014.07.010_b0830","doi-asserted-by":"crossref","first-page":"1929","DOI":"10.1126\/science.1132939","article-title":"The connectivity map: using gene-expression signatures to connect small molecules, genes, and disease","volume":"313","author":"Lamb","year":"2006","journal-title":"Science"},{"key":"10.1016\/j.jhep.2014.07.010_b0835","doi-asserted-by":"crossref","first-page":"707","DOI":"10.1016\/j.cell.2013.03.030","article-title":"Integrated systems approach identifies genetic nodes and networks in late-onset Alzheimer\u2019s disease","volume":"153","author":"Zhang","year":"2013","journal-title":"Cell"},{"key":"10.1016\/j.jhep.2014.07.010_b0840","doi-asserted-by":"crossref","first-page":"721","DOI":"10.1002\/msb.145122","article-title":"Identification of anticancer drugs for hepatocellular carcinoma through personalized genome-scale metabolic modeling","volume":"10","author":"Agren","year":"2014","journal-title":"Mol Syst Biol"}],"container-title":["Journal of Hepatology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0168827814004796?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0168827814004796?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2018,9,27]],"date-time":"2018-09-27T22:21:23Z","timestamp":1538086883000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0168827814004796"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2014,11]]},"references-count":168,"journal-issue":{"issue":"1","published-print":{"date-parts":[[2014,11]]}},"alternative-id":["S0168827814004796"],"URL":"https:\/\/doi.org\/10.1016\/j.jhep.2014.07.010","relation":{},"ISSN":["0168-8278"],"issn-type":[{"value":"0168-8278","type":"print"}],"subject":[],"published":{"date-parts":[[2014,11]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Pathogenesis and prevention of hepatitis C virus-induced hepatocellular carcinoma","name":"articletitle","label":"Article Title"},{"value":"Journal of Hepatology","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.jhep.2014.07.010","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2014 European Association for the Study of the Liver. Published by Elsevier B.V.","name":"copyright","label":"Copyright"}]}}